Kite, a Gilead (GILD), and Arcellx ( ACLX )announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies. Currently being investigated in a Phase 2 pivotal trial, CART-ddBCMA is Arcellx’s T-cell therapy utilizing the company’s novel synthetic binder, the D-Domain. Kite and Arcellx will jointly advance and commercialize the CART-ddBCMA asset in the U.S., and Kite will commercialize the product outside the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GILD:
- Gilead price target raised to $111 from $104 at Piper Sandler
- Truist biotech analyst to hold an industry dinner meeting
- Hookipa Pharma achieves $5M milestone payment from Gilead
- EVOQ to potentially receive $658.5M in Gilead collaboration on immunotherapies
- RBC downgrades Gilead, says drivers need time to play out